Aging, energy, and oxidative stress in neurodegenerative diseases
Corresponding Author
Dr M. Flint Beal MD
Neurochemistry Laboratory, Neurology Service, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Neurochemistry Laboratory, Warren 408, Massachusetts General Hospital, Boston, MA 02114Search for more papers by this authorCorresponding Author
Dr M. Flint Beal MD
Neurochemistry Laboratory, Neurology Service, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Neurochemistry Laboratory, Warren 408, Massachusetts General Hospital, Boston, MA 02114Search for more papers by this authorAbstract
The etiology of neurodegenerative diseases remains enigmatic; however, evidence for defects in energy metabolism, excitotoxicity, and for oxidative damage is increasingly compelling. It is likely that there is a complex interplay between these mechanisms. A defect in energy metabolism may lead to neuronal depolarization, activation of N-methyl-D-aspartate excitatory amino acid-receptors, and increases in intracellular calcium, which are buffered by mitochondria. Mitochondria are the major intracellular source of free radicals, and increased mitochondrial calcium concentrations enhance free radical generation. Mitochondrial DNA is particularly susceptible to oxidative stress, and there is evidence of age-dependent damage and deterioration of respiratory enzyme activities with normal aging. This may contribute to the delayed onset and age dependence of neurodegenerative diseases. There is evidence for increased oxidative damage to macromolecules in amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, and Alzheimer's disease. Potential therapeutic approaches include glutamate release inhibitors, excitatory amino acid antagonists, strategies to improve mitochondrial function, free radical scavengers, and trophic factors. All of these approaches appear promising in experimental studies and are now being applied to human studies.
References
- 1 Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 1992; 42: 733–738
- 2 Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992; 31: 119–130
- 3 Novelli A, Reilly JA, Lysko PG, et al. Glutamate becomes neurotoxic via the N-methyl-D-asparatate receptor when intracellular energy levels are reduced. Brain Res 1988; 451: 205–212
- 4 Zeevalk GD, Nicklas WJ. Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina. J Pharmacol Exp Ther 1990; 253: 1285–1292
- 5 Hartley DM, Kurth MC, Bjerkness L, et al. Glutamate receptor-induced 45Ca2+ accumulation in cortical cell culture correlates with subsequent neuronal degeneration. J Neurosci 1993; 13: 1993–2000
- 6 Tymianski M, Wallace MC, Spigelman I, et al. Cell-permeant Ca2+ chelators reduce early excitotoxic and ischemic neuronal injury in vitro and in vivo. Neuron 1993; 11: 221–235
- 7 Tymianski M, Charlton MP, Carlen PL, et al. Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons. J Neurosci 1993; 13: 2085–2104
- 8 Dawson VL, Dawson TM, London ED, et al. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 1991; 88: 6368–6371
- 9 Dawson VL, Dawson TM, Bartley DA, et al. Mechanisms of nitric oxide mediated neurotoxicity in primary brain cultures. J Neurosci 1993; 13: 2651–2661
- 10 Huang Z, Huang PL, Panahian N, et al. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 1994; 265: 1883–1885
- 11 Lafon-Cazal M, Pietri S, Culcasi M, et al. NMDA-dependent superoxide production and neurotoxicity. Nature 1993; 364: 535–537
- 12 Bondy SC, Lee DK. Oxidative stress induced by glutamate receptor agonists. Brain Res 1993; 610: 229–233
- 13 Chan PH, Chu L, Chen SF, et al. Reduced neurotoxicity in transgenic mice overexpressing human copper-zinc-superoxide dismutase. Stroke 1990; 21: 11180–11182
- 14 Schulz JB, Henshaw DR, Siwek D, et al. Involvement of free radicals in excitotoxicity in vivo. Neurochem 1995 (In press)
- 15 Chan PH, Chen J, Gafni J, et al. N-Methyl-D-aspartatemediated neurotoxicity is associated with oxygen-derived free radicals. Princeton Conf Cerebrovasc Dis 1995 (In press)
- 16 Liochev SI, Fridovich I. The role of O2·- in the production of HO·: in vitro and in vivo. Free Radic Biol Med 1994; 16: 29–33
- 17 Beckman JS, Crow JP. Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem Soc Trans 1993; 21: 330–334
- 18 Guidot DM, McCord JM, Wright RM, et al. Absence of electron transport (Rho° State) restores growth of a manganesesuperoxide dismutase-deficient Saccharomyces cerevisiae in hyperoxia. J Biol Chem 1993; 268: 26699–26703
- 19 Boveris A, Chance B. The mitochondrial generation of hydrogen peroxide. Biochem J 1973; 134: 707–716
- 20 Turrens JF, Boveris A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J 1980; 191: 421–427
- 21 De Jong AMP, Albracht SPJ. Ubisemiquinones as obligatory intermediates in the electron transfer from NADH to ubiquinone. Eur J Biochem 1994; 222: 975–982
- 22 Patole MS, Swaroop A, Ramasarma T. Generation of H2O2 in brain mitochondria. J Neurochem 1986; 47: 1–8
- 23 Werth JL, Thayer SA. Mitochondria buffer physiological calcium loads in cultured rat dorsal root ganglion neurons. J Neurosci 1994; 14: 348–356
- 24 Dykens JA. Isolated cerebral and cerebellar mitochondria produce free radicals when exposed to elevated Ca2+ and Na+: implications for neurodegeneration. J Neurochem 1994; 63: 584–591
- 25 Dugan LL, Sensi SL, Canzoniero LMT, et al. Imaging of mitochondrial oxygen radical production in cortical neurons exposed to NMDA. Soc Neurosci Abstr 1994; 20: 1532 (Abstract)
- 26 Richter C, Park J-W, Ames BN. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA 1988; 85: 6465–6467
- 27 Mecocci P, MacGarvey U, Kaufman AE, et al. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol 1993; 34: 609–616
- 28 Bowling AC, Mutisya EM, Walker LC, et al. Age-dependent impairment of mitochondrial function in primate brain. J Neurochem 1993; 60: 1964–1967
- 29 Di Monte DA, Sandy MS, DeLanney LE, et al. Age-dependent changes in mitochondrial energy production in striatum and cerebellum of the monkey brain. Neurodegeneration 1993; 2: 93–99
- 30 Cooper JM, Mann VM, Schapira AHV. Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: effect of aging. J Neurol Sci 1992; 113: 91–98
- 31 Boffoli D, Scacco SC, Vergari R, et al. Decline with age of the respiratory chain activity in human skeletal muscle. Biochim Biophys Acta 1994; 1226: 73–82
- 32 Cortopassi GA, Arnheim N. Detection of a specific mitochondrial DNA deletion in tissues of older humans. Nucleic Acids Res 1990; 18: 6927–6933
- 33 Corral-Debrinski M, Stepien G, Shoffner JM, et al. Hypoxemia is associated with mitochondrial DNA damage and geneinduction. JAMA 1991; 266: 1812–1816
- 34 Simonetti S, Chen X, DiMauro S, et al. Accumulation of deletions in human mitochondrial DNA during normal aging: analysis by quantitative PCR. Biochim Biophys Acta 1992; 1180: 113–122
- 35 Hattori K, Tanaka M, Sugiyama S, et al. Age-dependent increase in deleted mitochondrial DNA in the human heart: possible contributory factor to presbycardia. Am Heart J 1991; 121: 1735–1742
- 36 Sugiyama S, Hattori K, Hayakawa M, et al. Quantitative analysis of age-associated accumulation of mitochondrial DNA with deletion in human hearts. Biochem Biophys Res Commun 1991; 180: 894–899
- 37 Yen T-C, King K-L, Lee H-C, et al. Age-dependent increase of mitochondrial DNA deletions together with lipid peroxides and superoxide dismutase in human liver mitochondria. Free Radic Biol Med 1994; 16: 207–214
- 38 Soong NW, Hinton DR, Cortopassi G, et al. Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Nature Genet 1992; 2: 318–323
- 39 Corral-Debrinski M, Horton T, Lott MT, et al. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nature Genet 1992; 2: 324–329
- 40 Lee H-C, Pang C-Y, Hsu H-S, et al. Differential accumulations of 4,977 bp deletion in mitochondrial DNA of various tissues in human ageing. Biochem Biophys Acta 1994; 1226: 37–43
- 41 Munscher C, Muller-Hocker J, Kadenback B. The point mutation of mitochondrial DNA characteristic for MERRF disease is found also in healthy people of different ages. FEBS Lett 1993; 317: 27–30
- 42 Zhang C, Linnane AW, Nagley P. Occurrence of a particular base substitution (3243 A to G) in mitochondrial DNA of tissues of ageing humans. Biochem Biophys Res Commun 1993; 195: 1104–1110
- 43 Hayakawa M, Hattori K, Sugiyama S, et al. Age-associated accumulation of 8-hydroxydeoxyguanosine in mitochondrial DNA of human diaphragm. Biochem Biophys Res Commun 1991; 179: 1023–1029
- 44 Hayakawa M, Hattori K, Sugiyama S, et al. Age-associated oxygen damage and mutations in mitochondrial DNA in human hearts. Biochem Biophys Res Commun 1992; 189: 979–985
- 45 Chan P, DeLanney LE, Irwin I, et al. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J Neurochem 1991; 57: 348–351
- 46 Storey E, Hyman BT, Jenkins B, et al. 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J Neurochem 1992; 58: 1975–1978
- 47 Zuddas A, Oberto G, Vaglini F, et al. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates. J Neurochem 1992; 59: 733–739
- 48 Lange KW, Loschmann P-A, Sofic E, et al. The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 586–592
- 49 Deutsch AY, Rosin DL, Goldstein M, et al. 3-Acetylpyridine-induced degeneration of the nigrostriatal dopamine system: an animal model of olivopontocerebellar atrophy-associated parkinsonism. Exp Neurol 1989; 105: 1–9
- 50 Schulz JB, Henshaw DR, Jenkins BG, et al. 3-Acetylpyridine produces age-dependent excitotoxic lesions in rat striatum. J Cereb Blood Flow Metab 1994; 14: 1024–1029
- 51 Beal MF, Brouillet E, Jenkins BG, et al. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem 1993; 61: 1147–1150
- 52 Greene JG, Porter RHP, Eller RV, et al. Inhibition of succinate dehydrogenase by malonic acid produces an “excitotoxic” lesion in rat striatum. J Neurochem 1993; 61: 1151–1154
- 53 Henshaw R, Jenkins BG, Schulz JB, et al. Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Res 1994; 647: 161–166
- 54 Ludolph AC, He F, Spencer PS, et al. 3-Nitropropionic acid—exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 1991; 18: 492–498
- 55 Riepe M, Hori N, Ludolph AC, et al. Inhibition of energy metabolism by 3-nitropropionic acid activates ATP-sensitive potassium channels. Brain Res 1992; 586: 61–66
- 56 Ludolph AC, Seelig M, Ludolph A, et al. 3-Nitropropionic acid decreases cellular energy levels and causes neuronal degeneration in cortical explants. Neurodegeneration 1992; 1: 155–161
- 57 Weller M, Paul SM. 3-Nitropropionic acid is an indirect excitotoxin to cultured cerebellar granule neurons. Eur J Pharmacol 1993; 248: 223–228
- 58 Brouillet E, Jenkins BG, Hyman BT, et al. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 1993; 60: 356–359
- 59 Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histologic characterization of striatal excitoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993; 13: 4181–4192
- 60 Wullner U, Young AB, Penney JB, et al. 3-Nitropropionic acid toxicity in the striatum. J Neurochem 1994; 63: 1772–1781
- 61 Brouillet E, Hantraye P, Dolan R, et al. Chronic administration of 3-nitropropionic acid induced selective striatal degeneration and abnormal choreiform movements in monkeys. Soc Neurosci Abstr 1993; 19: 409 (Abstract)
- 62 Przedborski S, Kostic V, Jackson-Lewis V, et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced neurotoxicity. J Neurosci 1992; 12: 1658–1667
- 63 Schulz JB, Matthews RT, Muqit MMK, et al. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 1995; 64: 936–939
- 64 Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59–62
- 65 Deng H-X, Hentati A, Tainer JA, et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 1993; 261: 1047–1051
- 66 Bowling AC, Schulz JB, Brown RH Jr, et al. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyortrophic lateral sclerosis. J Neurochem 1993; 61: 2322–2325
- 67 Beckman JS, Carson M, Smith CD, et al. ALS, SOD and peroxynitrite. Nature 1993; 364: 584 (Letter)
- 68 Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994; 264: 1772–1775
- 69 Rothstein JD, Bristol LA, Hosler B, et al. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sci USA 1994; 91: 4155–4159
- 70 Schapira AHV, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990; 55: 2142–2145
- 71 Janetzky B, Hauck S, Youdim MBH, et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigrapars compacta of patients with Parkinson's disease. Neurosci Lett 1994; 169: 126–128
- 72 Hattori N, Tanaka M, Ozawa T, et al. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann Neurol 1991; 30: 563–571
- 73 Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989; 26: 719–723
- 74 Haas RH, Nasirian F, Ward D, et al. Low platelet mitochon drial complex I activity in untreated early Parkinson disease. Neurology 1994; 44 (suppl 2): A178 (Abstract)
- 75 Benecke R, Strumper P, Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain 1993; 116: 1451–1463
- 76 Eberling JL, Richardson BC, Reed BR, et al. Cortical glucose metabolism in Parkinson's disease without dementia. Neurobiol Aging 1994; 15: 329–335
- 77 Bowen BC, Block RE, Sanchez-Ramos J, et al. Proton MR spectroscopy of the brain in 14 patients with Parkinsn's disease. Am J Neuroradiol 1994 (In press)
- 78 Chen YI, Jenkins BG, Rosen BR, Evidence for impairment of energy metabolim in Parkinson's disease using in vivo localized MR spectroscopy. Proc Soc Magn Res 1994; 1: 194 (Abstract)
- 79 Shoffner JM, Brown MD, Torroni A, et al. Mitochondrial DNA mutations associated with Alzheimer's and Parkinson's disease. Genomics 1993; 17: 171–184
- 80 Dexter DT, Holley AE, Flitter WD, et al. Increased levels of lipid hydroperoxides in the Parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994; 9: 92–97
- 81 Sanchez-Ramos JR, Overvik E, Ames BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 1994; 3: 197–204
- 82 Sofic E, Lange KW, Jellinger K, et al. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992; 142: 128–130
- 83 Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994; 36: 348–355
- 84 Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994; 35: 38–44
- 85 Jenkins B, Koroshetz W, Beal MF, et al. Evidence for an energy metabolism defect in Huntington's disease using localized proton spectroscopy. Neurology 1993; 43: 2689–2695
- 86 Koroshetz WJ, Jenkins B, Rosen B, et al. Evidence for a metabolic disorder in Huntington's disease. Neurology 1994; 44:(suppl 2): A338 (Abstract)
- 87 Parker WD Jr, Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 1990; 40: 1302–1303
- 88 Kish SJ, Bergeron C, Rajput A, et al. Brain cytochrome oxidase in Alzheimer's disease. J Neurochem 1992; 59: 776–779
- 89 Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 1994; 63: 2179–2184
- 90 Parker WD, Parks J, Filley CM, et al. Electron transport chain defects in Alzheimer's disease brain. Neurology 1994; 44: 1090–1096
- 91 Chandrasekaran K, Giordano T, Brady DR, et al. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. Mol Brain Res 1994; 24: 336–340
- 92 Simonian NA, Hyman BT. Functional alterations in Alzheimer's disease: diminution of cytochrome oxidase in hippocampal formation. J Neuropathol Exp Neurol 1993; 52: 580–585
- 93 Chandrasekaran K, Stoll J, Brady DR, et al. Localization of cytochrome oxidase (COX) activity and COX mRNA in the hippocampus and entorhinal cortex of the monkey brain: correlation with specific neuronal pathway. Brain Res 1992; 579: 333–336
- 94 Subbarao KV, Richardson JS, Ang LC. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 1990; 55: 342–345
- 95 Hajimohammadreza I, Brammer M. Brain membrane fluidity and lipid peroxidation in Alzheimer's disease. Neurosci Lett 1990; 112: 333–337
- 96 Palmer AM, Burns MA. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res 1994; 645: 338–342
- 97 Smith CD, Carney JM, Starke-Reed PE, et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer disease. Proc Natl Acad Sci USA 1991; 88: 10540–10543
- 98 Pappolla MA, Omar RA, Kim KS, et al. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease. Am J Pathol 1992; 140: 621–628
- 99 Yan S-D, Chen X, Schmidt A-M, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994; 91: 7787–7791
- 100 Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994; 36: 747–751
- 101 Gabuzda D, Busciglio J, Chen LB, et al. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 1994; 6: 13623–13628
- 102 Dyrks T, Dyrks E, Masters CL, et al. Amyloidogenicity of rodent and human βA4 sequences. FEBS Lett 1993; 324: 231–236
- 103 Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onser Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 8098–8102
- 104 Jun AS, Brown MD, Wallace DC. A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia. Proc Natl Acad Sci USA 1994; 91: 6206–6210
- 105 Jones-Humble SA, Morgan PF, Cooper BR. The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease. Life Sci 1994; 54: 245–252
- 106 Bensimon G, Lacomblez L, Meininger V, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585–591
- 107 Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330: 613–622
- 108 Noack H, Kube U, Augustin W. Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria. Free Radic Res 1994; 20: 375–386
- 109 Favit A, Nicoletti F, Scapagnini U, et al. Ubiquinone protects cultured neurons against spontaneous and excitotoxin-induced degeneration. J Cereb Blood Flow Metab 1992; 12: 638–645
- 110 Beal MF, Henshaw R, Jenkins BG, et al. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 1994; 36: 882–88
- 111 Koroshetz W, Jenkins B, Rosen B, et al. Ubiquinone lowers occipital lactate levels in patients with Huntington's disease. Neurology 1993; 43 (suppl 2): A334 (Abstract)
- 112 Oliver CN, Starke RP, Stadtman ER, et al. Oxidative damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during ischemia/reperfusioninduced injury to gerbil brain. Proc Natl Acad Sci USA 1990; 87: 5144–5147
- 113 Cao X, Phillis JW. α-Phenyl-tert-butyl-nitrone reduces cortical infarct and edema in rats subjected to focal ischemia. Brain Res 1994; 644: 267–272
- 114 Hall ED. Cerebral ischemia, free radicals and antioxidant protection. Biochem Soc Trans 1993; 21: 334–339
- 115 Greenamyre JT, Garcia-Osuna M, Greene JG. The endogenous cofactors, thioctic acid and dihydrolipoic acid, are neuroprotective against NMDA and malonic acid lesions of striatum. Neurosci Lett 1994; 171: 17–20
- 116 Mattson MP, Zhang Y, Bose S. Growth factors prevent mitochondrial dysfunction, loss of calcium homeostasis, and cell injury, but not ATP depletion in hippocampal neurons deprived of glucose. Exp Neurol 1993; 121: 1–13
- 117 Zhang Y, Tatsuno T, Carney JM, et al. Basic FGF, NGF, and IGFs protect hippocampal and cortical neurons against iron-induced degeneration. J Cereb Blood Flow Metab 1993; 13: 378–388